{
    "nct_id": "NCT03715829",
    "official_title": "A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06651600 WITH A PARTIALLY BLINDED EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF PF-06651600 AND PF-06700841 IN SUBJECTS WITH ACTIVE NON-SEGMENTAL VITILIGO",
    "inclusion_criteria": "* Male or female subjects between 18-65 years of age, inclusive, at time of informed consent.\n* Must have moderate to severe active non-segmental vitiligo.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 65 Years",
    "exclusion_criteria": "* History of human immunodeficiency virus (HIV) or positive HIV serology at screening,\n* Infected with hepatitis B or hepatitis C viruses.\n* Have evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB)",
    "miscellaneous_criteria": ""
}